Moxifloxacin Stulln (Moxifloxacin)

Moxifloxacin Stulln is a fluoroquinolone antibacterial indicated for several ocular bacterial infections.

• Bacterial conjunctivitis: reduces bacterial load and accelerates resolution of redness and discharge.
• Bacterial keratitis: eradicates causative organisms to prevent corneal damage and preserve vision.
• Other ocular bacterial infections: treats infections of the eyelid, sclera or intra‑ocular structures caused by susceptible bacteria.

• Moxifloxacin inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, enzymes essential for DNA replication, transcription and repair. By blocking these targets, the drug prevents bacterial cell division and leads to bacterial cell death, providing a bactericidal effect against a broad spectrum of Gram‑positive and Gram‑negative ocular pathogens.

Moxifloxacin Stulln may cause local ocular reactions and, rarely, systemic hypersensitivity.

Common Side Effects

• Burning or stinging sensation upon instillation.
• Temporary blurred vision.
• Redness of the conjunctiva.
• Tearing or increased lacrimation.
• Foreign body sensation.
• Mild eye irritation.

Serious or Rare Side Effects

• Allergic reaction (e.g., eyelid edema, rash).
• Corneal ulceration or perforation.
• Severe eye pain.
• Vision loss.
• Stevens‑Johnson syndrome or toxic epidermal necrolysis.
• Systemic hypersensitivity (rare).

Before using Moxifloxacin Stulln, consider the following safety measures.

• Allergy assessment: avoid if the patient has known hypersensitivity to fluoroquinolones.
• Contact lens wearers: remove lenses before instillation and wait before reinserting.
• Pregnancy and lactation: use only if the prescriber determines potential benefits outweigh risks.
• Concomitant ocular conditions: monitor closely in patients with corneal epithelial defects.
• Systemic absorption: caution in patients on medications that may prolong QT interval.
• Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Moxifloxacin Stulln can interact with systemic agents and ocular products.

Major Interactions (Avoid)

• Systemic fluoroquinolones combined with drugs that prolong QT interval (e.g., quinidine, amiodarone).
• Co‑administration with ophthalmic corticosteroids without close monitoring.

Moderate Interactions (Monitor Closely)

• Antacids, sucralfate or multivitamins containing calcium, magnesium, aluminum, or iron that may reduce ocular absorption.
• Non‑steroidal anti‑inflammatory eye drops that could increase risk of corneal toxicity.
• Other topical antibiotics that may cause additive ocular irritation.
• Systemic drugs that affect wound healing (e.g., systemic steroids).